This precursor peptide consists of a signal peptide, a glucagon-related polypeptide, glucagon, and GLP-1 and GLP-2
The final CY 2026 ASC payment rates listed in Addendum BB for separately payable drugs and biologicals are based on the most recently available data used for payment in physicians' offices
Safety and Tolerability Cerebrolysin: Well-Established Safety Profile Cerebrolysin benefits from decades of post-marketing surveillance and clinical trial safety data: Clinical Trial Safety: Across multiple RCTs, Cerebrolysin has demonstrated a tolerability profile comparable to placebo in most studies, with adverse events generally mild and transient Common Side Effects: Injection site reactions, dizziness, headache, and nausea are the most frequently reported adverse events at standard clinical doses Serious Adverse Events: Rare at therapeutic doses
Equine melanotic disease
initial, up to 1 hour. This number is used for the first hour of a medically essential IV infusion
Talk with your doctor if you have questions or concerns about side effects
